Supplementary Figure S1 from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal Jhaveri; Meritxell Bellet; Nicholas C. Turner; Sherene Loi; Aditya Bardia; Valentina Boni; Joohyuk Sohn; Tomas G. Neilan; Rafael Villanueva-Vázquez; Peter Kabos; Laura García‐Estévez; Elena López-Miranda; José Alejandro Pérez Fidalgo; José Manuel Pérez-García; Jiajie Yu; Jill Fredrickson; Heather M. Moore; Ching‐Wei Chang; John W. Bond; Jennifer Eng‐Wong; Mary Gates; Elgene Lim

doi:10.1158/1078-0432.25232192

Abstract

Figure S1. Best confirmed response by specific baseline ESR1 mutation: single-agent giredestrant ±LHRH agonist cohorts (A) and giredestrant +palbociclib ±LHRH agonist cohorts (B).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jhaveri et al. (2024) studied this question.

synapsesocial.com/papers/68e78f4db6db6435877008ba https://doi.org/10.1158/1078-0432.25232192

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S1 from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers